Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US5573762A · kind A · utility
9Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 1995 |
| Grant date | Nov 12, 1996 |
| Priority date | — |
| Expiry date | Apr 24, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/3955
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.